Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Teva elects David J. Brailer to board, effective November 3, 2026

Neutral Impact 2 of 5 leadership Written later

Teva's board elected Dr. David J. Brailer as a director, effective November 3, 2026, serving until the 2027 annual meeting. The board determined he is independent under NYSE rules and expects him to join the Human Resources and Compensation and Compliance Committees. The filing says he will receive the same non-executive director compensation described in the March 31, 2026 proxy statement.

Key points

  • Board elected Dr. David J. Brailer on October 27, 2026, effective November 3, 2026
  • Term runs until Teva's 2027 annual meeting of shareholders
  • Board determined he is independent under NYSE listing rules; expected to serve on Human Resources and Compensation and Compliance Committees
  • Formerly Chief Health Officer of The Cigna Group (2022 to 2026) and former director of Walgreens Boots Alliance (2012 to 2021)

The filing

CompanyTEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
Form8-K, current report
Filed with the SECOct 29, 2026, 5:08 PM ET
Accession number0001193125-26-438019

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.